

## **Ongoing Disclosure Notice**

## **Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Serko Limited
Date this disclosure made:	2-Jul-20
Date of last disclosure:	8-Jun-21
Date of last disclosure.	0-Juli-21
Director or senior manager giving disclosure	
Full name(s):	Claudia Batten
Name of listed issuer:	Serko Limited
Name of related body corporate (if applicable):	Not applicable
Position held in listed issuer:	Director
r osition field in listed issuer.	Director
I Summary of acquisition or disposal of relevant interest (excluding specified derivatives)	
Class of affected quoted financial products:	Ordinary shares
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
The tare of the directed relevant medical(s).	negotered notice and senemal office
For that relevant interest-	
Number held in class before acquisition or disposal:	81,818
Number held in class after acquisition or disposal:	83,454
Current registered holder(s):	Not applicable
Registered holder(s) once transfers are registered:	Claudia Batten
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	
Details of transactions requiring disclosure-	
Date of transaction:	1-Jul-20
Nature of transaction:	Issue of ordinary shares.
Name of any other party or parties to the transaction (if known):	Not applicable
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or	The Shares are being issued, in lieu of cash, in part consideration for service
disposal. If the consideration was not in cash and cannot be readily converted into a cash value	provided by Ms Batten in her role as a non-executive director of the
describe the consideration:	Company, for the period 1 April 2020 to 30 June 2020, to a value
	(representing 15% of her director remuneration for this period) of
	NZ\$5,381.63. This is intended to assist Serko's cashflow during the Covid-
	affected period. The issue price was NZ\$3.29 per Ordinary Share, being the
	day volume weighted average market price of Serko Limited's ordinary
	shares on the NZX through to 30 June 2020
	4 606 11
Number of financial products to which the transaction related:	1,636 ordinary shares
If the issuer has a financial products trading policy that prohibits directors or senior managers	
from trading during any period without written clearance (a closed period) include the following	
details—	
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed	Not applicable
during the closed period:	
Date of the prior written clearance (if any):	Not applicable
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	Ordinary shares
Nature of relevant interest:	Beneficial owner of ordinary shares held in custody for Claudia Batten
	pursuant to Non-Executive Director Fixed Trading Plan
For that relevant interest,-	
Number held in class:	37,066.56 ordinary shares
Current registered holder(s):	Custodian Services Limited as custodian for Claudia Batten

**Details of derivative,-**The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

For a derivative relevant interest,-

Type of derivative:

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

products:	, ,		
For that derivative relevant interest,-	,		
Parties to the derivative:	,	Not applicable	
If the director or senior manager is not a party to the derivative, the nature of the relevant	, ,	Not applicable	
interest in the derivative:	,		
Certification			
I certify that, to the best of my knowledge and belief, the information contained in this disclosu	1		
is correct and that I am duly authorised to make this disclosure by all persons for whom it is	1		
made.	i		
Signature of director or officer:			
Date of signature:	,		1-Jul-20

Not applicable

Not applicable

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under t

derivative or the value of the derivative is affected by the value of the underlying financial